Cargando…
1814. External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections
BACKGROUND: ILÚM Heath Solutions, an infectious diseases software platform, developed precision antibiotic therapy (PAT) software to guide selection of therapy using data science, patient-specific factors, as well as historical patient, pharmacy, and microbiologic data. PAT reports percentages refle...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254180/ http://dx.doi.org/10.1093/ofid/ofy210.1470 |
_version_ | 1783373665361985536 |
---|---|
author | Lee, Tiffany White, Melissa Overly, Shannon Mehta, Jimish Binkley, Shawn Morgan, Steven Saw, Stephen Hamilton, Keith |
author_facet | Lee, Tiffany White, Melissa Overly, Shannon Mehta, Jimish Binkley, Shawn Morgan, Steven Saw, Stephen Hamilton, Keith |
author_sort | Lee, Tiffany |
collection | PubMed |
description | BACKGROUND: ILÚM Heath Solutions, an infectious diseases software platform, developed precision antibiotic therapy (PAT) software to guide selection of therapy using data science, patient-specific factors, as well as historical patient, pharmacy, and microbiologic data. PAT reports percentages reflecting likelihood of susceptibility across a panel of antibiotics, identifying patients at high risk for resistant organisms. PAT has previously demonstrated high accuracy for predicting susceptibility of Enterobacteriaceae in bloodstream infections (BSIs) and risk for multi-drug resistance. The objective of this study was to validate PAT predictive capabilities in enterococcal BSIs and to assess accuracy in risk-stratifying patients for vancomycin-resistant Enterococcus spp. (VRE). METHODS: This retrospective cohort study included patients with an index enterococcal BSI from January 2016 through December 2016. The primary outcome was the performance characteristics of PAT in accurately predicting the risk of VRE, elaborated with sensitivity and specificity rates across varying PAT thresholds. Receiver operating characteristics (ROC) curve analyses were performed to identify an acceptable PAT threshold to define high risk for VRE. Brier score calculations were used to compare accuracy of PAT predictions to that of the institutional antibiogram. RESULTS: ROC curve analysis (Figure 1) demonstrated an area under the curve of 0.94, indicating excellent discrimination. The Brier scores for the institutional antibiogram and PAT software were 0.067 and 0.075, respectively, representing a similar degree in accuracy. Species-level Brier scores for the institutional antibiogram and PAT were 0.043 and 0.065, respectively, for E. faecalis and 0.093 and 0.073, respectively, for E. faecium. CONCLUSION: PAT software was able to discriminate enterococcal BSIs resistant and susceptible to vancomycin. Similar to previous results seen with Enterobacteriaceae, PAT may be useful to accurately predict susceptibilities for Enterococcus spp., particularly for E. faecium. DISCLOSURES: S. Overly, ILÚM Health Solutions: Consultant, Salary. J. Mehta, ILUM Health Solutions: Consultant, Salary. |
format | Online Article Text |
id | pubmed-6254180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62541802018-11-28 1814. External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections Lee, Tiffany White, Melissa Overly, Shannon Mehta, Jimish Binkley, Shawn Morgan, Steven Saw, Stephen Hamilton, Keith Open Forum Infect Dis Abstracts BACKGROUND: ILÚM Heath Solutions, an infectious diseases software platform, developed precision antibiotic therapy (PAT) software to guide selection of therapy using data science, patient-specific factors, as well as historical patient, pharmacy, and microbiologic data. PAT reports percentages reflecting likelihood of susceptibility across a panel of antibiotics, identifying patients at high risk for resistant organisms. PAT has previously demonstrated high accuracy for predicting susceptibility of Enterobacteriaceae in bloodstream infections (BSIs) and risk for multi-drug resistance. The objective of this study was to validate PAT predictive capabilities in enterococcal BSIs and to assess accuracy in risk-stratifying patients for vancomycin-resistant Enterococcus spp. (VRE). METHODS: This retrospective cohort study included patients with an index enterococcal BSI from January 2016 through December 2016. The primary outcome was the performance characteristics of PAT in accurately predicting the risk of VRE, elaborated with sensitivity and specificity rates across varying PAT thresholds. Receiver operating characteristics (ROC) curve analyses were performed to identify an acceptable PAT threshold to define high risk for VRE. Brier score calculations were used to compare accuracy of PAT predictions to that of the institutional antibiogram. RESULTS: ROC curve analysis (Figure 1) demonstrated an area under the curve of 0.94, indicating excellent discrimination. The Brier scores for the institutional antibiogram and PAT software were 0.067 and 0.075, respectively, representing a similar degree in accuracy. Species-level Brier scores for the institutional antibiogram and PAT were 0.043 and 0.065, respectively, for E. faecalis and 0.093 and 0.073, respectively, for E. faecium. CONCLUSION: PAT software was able to discriminate enterococcal BSIs resistant and susceptible to vancomycin. Similar to previous results seen with Enterobacteriaceae, PAT may be useful to accurately predict susceptibilities for Enterococcus spp., particularly for E. faecium. DISCLOSURES: S. Overly, ILÚM Health Solutions: Consultant, Salary. J. Mehta, ILUM Health Solutions: Consultant, Salary. Oxford University Press 2018-11-26 /pmc/articles/PMC6254180/ http://dx.doi.org/10.1093/ofid/ofy210.1470 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Lee, Tiffany White, Melissa Overly, Shannon Mehta, Jimish Binkley, Shawn Morgan, Steven Saw, Stephen Hamilton, Keith 1814. External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections |
title | 1814. External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections |
title_full | 1814. External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections |
title_fullStr | 1814. External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections |
title_full_unstemmed | 1814. External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections |
title_short | 1814. External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections |
title_sort | 1814. external validation of precision antibiotic therapy for enterococcal bloodstream infections |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254180/ http://dx.doi.org/10.1093/ofid/ofy210.1470 |
work_keys_str_mv | AT leetiffany 1814externalvalidationofprecisionantibiotictherapyforenterococcalbloodstreaminfections AT whitemelissa 1814externalvalidationofprecisionantibiotictherapyforenterococcalbloodstreaminfections AT overlyshannon 1814externalvalidationofprecisionantibiotictherapyforenterococcalbloodstreaminfections AT mehtajimish 1814externalvalidationofprecisionantibiotictherapyforenterococcalbloodstreaminfections AT binkleyshawn 1814externalvalidationofprecisionantibiotictherapyforenterococcalbloodstreaminfections AT morgansteven 1814externalvalidationofprecisionantibiotictherapyforenterococcalbloodstreaminfections AT sawstephen 1814externalvalidationofprecisionantibiotictherapyforenterococcalbloodstreaminfections AT hamiltonkeith 1814externalvalidationofprecisionantibiotictherapyforenterococcalbloodstreaminfections |